Premium
Blood donation and transfusion practices: the 1990 American Association of Blood Banks Institutional Membership Questionnaire
Author(s) -
Devine P.,
Postoway N.,
Hoffstadter L.,
Surgenor D.M.,
Linden J.V.,
Hines D.,
Chernoff A.,
Ciavarella D.,
Bove J.R.
Publication year - 1992
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1992.32792391046.x
Subject(s) - medicine , cryoprecipitate , donation , blood transfusion , hematocrit , blood type (non human) , transfusion medicine , hepatitis b , whole blood , surgery , abo blood group system , emergency medicine , platelet , economics , economic growth
Responses to the 1990 American Association of Blood Banks (AABB) Institutional Membership Questionnaire were submitted by 2126 regional blood centers, hospital‐based blood banks, and transfusion facilities. Data from 2117 of these facilities were considered to be valid. The questionnaire included information on blood donor demographics, number of units collected, and collection procedures; services performed; usage of blood components; and transfusion‐transmitted diseases reported during 1989. Institutional members collected 7.4 million whole blood units, of which 90.8 percent were donated for allogeneic use, 6.0 percent were donated for autologous use, and 3.2 percent were donated for directed use. Approximately 630,546 allogeneic and directed‐use blood donors were deferred, most often for low hemoglobin or hematocrit values. Approximately 225,205 full allogeneic and directed‐donor units were discarded, primarily for elevated alanine aminotransferase levels or the presence of hepatitis B core antibody. The 14.3 million transfused components included 56.7 percent red cell‐containing components, 27.4 percent platelets, 11 percent fresh‐frozen plasma, and 4.8 percent cryoprecipitate. Institutional members reported 1397 cases of transfusion‐associated hepatitis. In this group, 921 patients were tested for hepatitis B surface antigen after the transfusion; 339 (36.8%) were found to be hepatitis B surface antigen positive. The AABB Institutional Questionnaire results provide recent data on blood donor and transfusion‐related activities that are vital to the evaluation of current transfusion medicine practices.